Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Anchor lead: How can technology help support people to age as well as possible? Elizabeth Tracey reports Can engineering technologies enable help older people age in place? That’s one hope of the Malone Center for Engineering in Healthcare at Johns …
Podcast: Download (Duration: 1:02 — 1.4MB)
Subscribe: RSS
Anchor lead: One of the biggest barriers for some people with chronic illness is access to care, Elizabeth Tracey reports ‘Social determinants of health’ is one of the most used buzz-phrases currently, identifying someone’s social factors as primary in determining …
Podcast: Download (Duration: 1:03 — 1.4MB)
Subscribe: RSS
Anchor lead: A comprehensive approach to healthcare benefits all, Elizabeth Tracey reports A program known as J-ChiP, for Johns Hopkins Community Partnership, not only saves millions of dollars in healthcare costs for people with chronic illness, it creates an entire …
Podcast: Download (Duration: 1:06 — 1.5MB)
Subscribe: RSS
Anchor lead: Can a community peer help people avoid hospitalization? Elizabeth Tracey reports Do you know what a community health worker is? This is someone from the neighborhood who helps a person with chronic illness manage their social issues, such …
Podcast: Download (Duration: 0:59 — 1.4MB)
Subscribe: RSS
Anchor lead: A new series puts the social aspects of health front and center, Elizabeth Tracey reports What are social determinants of health? A new series in the New England Journal of Medicine examines how things like education, neighborhoods, income …
Podcast: Download (Duration: 1:02 — 1.4MB)
Subscribe: RSS
Anchor lead: Psilocybin’s list of conditions where it may help is expanding, Elizabeth Tracey reports The FDA is reviewing whether the hallucinogenic drug psilocybin should be reclassified to acknowledge areas where it is clinically useful, at the urging of Matthew …
Podcast: Download (Duration: 1:03 — 1.4MB)
Subscribe: RSS
Anchor lead: Should the FDA approve psilocybin as a medicine? Elizabeth Tracey reports Psilocybin is a drug that the FDA currently categorizes as having no clinical value, but an initiative underway at Johns Hopkins and several other research facilities is …
